Zymeworks shifts to a royalty-driven business model
Source: SeekingAlpha
2025-11-18 12:24:45 ET
More on Zymeworks
- Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
- Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity
- Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
- Jazz, Zymeworks’ Ziihera trial shows significant PFS improvement, shares rally
- Zymeworks outlines capital allocation strategy and expands ADC pipeline while targeting funding through 2027
Read the full article on Seeking Alpha
For further details see:
Zymeworks shifts to a royalty-driven business model
BeiGene
NASDAQ: BEIGF
BEIGF Trading
0.0% G/L:
$23.75 Last:
100 Volume:
$23.75 Open:
BEIGF Latest News
BEIGF Stock Data
$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel
